



- DISPERSE2 was a double-blind, double-dummy, parallel-group, randomized dose-confirmation and feasibility study of AZD6140 in addition to standard therapy with aspirin (75–100 mg qd) compared with clopidogrel combined with aspirin
- Treatment period was 4–12 weeks, with assessments at Weeks 4, 8, and 12, and a follow-up telephone call 7 days after the last visit
- 50% of patients in each AZD6140 arm received a loading dose of 270 mg
- In the clopidogrel arm, thienopyridine treatment-naive patients received a 300-mg loading dose



Primary Endpoint: Total Bleeding

